Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
Ascendis Pharma A/S Announces Second Quarter 2020 Financial Results and Business Update Conference Call on August 27
08:01pm, Thursday, 13'th Aug 2020
COPENHAGEN, Denmark, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical ne
Ascendis' Dwarfism Candidate Gets Orphan Drug Status in EU
04:48pm, Thursday, 13'th Aug 2020
Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ CNP for the Treatment of Achondroplasia in Europe
11:05am, Wednesday, 12'th Aug 2020
COPENHAGEN, Denmark, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs
Rockwell Automation Holding Up On Recovery And Reshoring Expectations (NYSE:ROK)
06:29pm, Tuesday, 04'th Aug 2020
Rockwell posted a modest segment-level beat in the fiscal third quarter, with better results in the A&S segment.
Ascendis Pharma A/S Announces Upcoming Investor Presentations in August
12:30pm, Tuesday, 04'th Aug 2020
COPENHAGEN, Denmark, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical ne
Altra Industrial Motion Corp (AIMC) Q2 2020 Earnings Call Transcript | The Motley Fool
08:30pm, Friday, 24'th Jul 2020
AIMC earnings call for the period ending June 30, 2020.
Why Ascendis Pharma (ASND) Stock is a Compelling Investment Case
01:47pm, Friday, 24'th Jul 2020
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Mid-Cap Growth Fund posted a return of 31.64% for the quarter, outperforming its benchmark, the
Altra Industrial Motion Corp. : Announces Third Quarter 2020 Dividend | MarketScreener
04:57pm, Wednesday, 22'nd Jul 2020Vident Investment Advisory LLC Buys New Shares in Ascendis Pharma A/S (NASDAQ:ASND)
06:22am, Wednesday, 22'nd Jul 2020
Vident Investment Advisory LLC purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Co
Ascendis Pharma A/S (NASDAQ:ASND) Lowered to Sell at Zacks Investment Research
05:26am, Tuesday, 14'th Jul 2020
Zacks Investment Research cut shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a sell rating in a research report released on Monday morning, Zacks.com reports. According to Zacks, �
Did Hedge Funds Make The Right Call On Ascendis Pharma A/S (ASND) ?
12:49am, Saturday, 11'th Jul 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
02:11am, Wednesday, 08'th Jul 2020
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced the pricing of its underwritten public off
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
12:00am, Wednesday, 08'th Jul 2020
COPENHAGEN, Denmark, July 07, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative...
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
04:58pm, Monday, 06'th Jul 2020
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that it has commenced an underwritten publ
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that it received a positive opinion from the
